Pheochromocytomas (PHEO) (1-3) are catecholamineproducing tumors that arise from chromaffin cells. PHEO are mostly situated within the adrenal medulla, although in about 9 -23% of cases, tumors develop from extraadrenal chromaffin tissue (adjacent to sympathetic ganglia of the neck, mediastinum, abdomen, and pelvis) and are often referred to as paragangliomas (4 -6).
erated upon, suffering additional surgery-related complications and substantial financial expenses. Some clinicians consider the presence of sporadic unilateral small PHEO as indicative of benign disease. This was concluded in older studies of series of patients with PHEO (23-25). However, more recent works from large series of patients with benign and malignant disease in the United States and Europe do not support this view; rather, they support the opinion that there are no absolute clinical, imaging, or laboratory criteria to predict malignancy and clinical course of PHEO (5, 16, 19, 26 -32) . Nevertheless, PHEO tumors with a diameter larger than 5 cm have a higher potential to metastasize, and such patients should be followed more frequently (33). Consequently, it seems that ruling out metastatic PHEO before initial surgery would be useful, because the detection of other lesions may dramatically affect treatment and follow-up.
Localization of PHEO should be attempted using at least two imaging modalities. Anatomical imaging studies [computed tomography (CT) and magnetic resonance imaging (MRI)] should be combined with functional (nuclear medicine) imaging studies for optimal results to locate primary, recurrent, or metastatic PHEO.
Functional imaging studies (enabled by the presence of the noradrenergic transporter system on PHEO cells) include [ 123 11 C]epinephrine positron emission tomography (PET) (34 -38). Chromaffin cells in various neuroendocrine tissues [such as PHEO, but also medullary thyroid carcinoma (MTC)] express the plasma membrane norepinephrine transporter and the intracellular vesicular monoamine transporter. The norepinephrine transporter is responsible for the cellular uptake of both MIBG (39) and [ 18 F]DA (36). We have recently shown that [ 18 F]DA PET scanning could theoretically represent yet another imaging modality for the detection of MTCs (40) because MTC cells often express the norepinephrine transporter and concentrate MIBG (41).
In most cases, functional imaging modalities are either able to confirm that a tumor is a PHEO or can lead to further diagnostic work-up. For example, in a patient with positive plasma metanephrines and MIBG imaging studies showing uptake in extraadrenal locations, the possible presence of multiple endocrine neoplasia type 2 (MEN 2)-related tumors (including MTC) should be considered and assessed with measurement of serum calcitonin and/or RET mutations.
Functional imaging studies are also very helpful to rule out metastatic disease in most cases. However, as malignant PHEO may undergo tumor dedifferentiation with loss of specific neurotransmitter transporters (Refs. 42 and 43, and Pacak, K., unpublished observation), leading to the inability to accumulate these isotopes and consequent lack of localization, [ 18 F]fluorodeoxyglucose ([ 18 F]FDG) PET scanning or somatostatin receptor scintigraphy (Octreoscan) may be required as the next step of the imaging algorithm. [ 18 F]FDG is a nonspecific imaging agent whose accumulation is based on the higher metabolic rate of tumors compared with surrounding normal tissue. Another characteristic of dedifferentiated tumors is either the loss or the gain of specific receptors. More particularly, malignant PHEO often expresses somatostatin receptors (44 -47), thus enabling scintigraphy with the somatostatin analog octreotide.
In this review we provide readers with current views of the roles of various imaging modalities for biochemically proven PHEO based on elevated plasma metanephrines (36, 48 -50) with emphasis on new functional PET imaging agents. Furthermore, we recommend an algorithm implementing anatomical and functional imaging modalities to assure proper localization of benign and malignant PHEO. The proposed algorithm serves not only to localize PHEO, but also to confirm that a tumor is indeed a PHEO and to differentiate adrenal tumors, including incidentalomas from PHEO. Whenever possible, in treating benign or malignant PHEO, surgical excision of any accessible mass should be considered (13, 51-54), because it may alleviate symptoms from catecholamine excess, improve quality of life, and possibly in some patients with only osseous metastatic lesions help to increase their survival. However, in the presence of extensive organ metastatic lesions, the removal of primary lesions and incomplete removal of metastatic lesions in organs are not considered to have an effect on the patients' survival (55), although further studies are needed. The proposed algorithm serves to guide and optimize surgery in patients with adrenal and extraadrenal PHEOs. Finally, although no cost-effectiveness analyses of PHEO localization have yet been performed, we believe that our approach deals with some "cost" issues, including less radiation exposure to patients.
Anatomical imaging
CT and MRI are common initial imaging modalities used for the localization of PHEO. These studies localize PHEO with high sensitivity, but less than optimal specificity. As these imaging modalities are currently less expensive and time consuming as well as more readily available than functional imaging studies, they should be used as first line imaging modalities. In addition, they should always be carried out over the abdomen first, because PHEO are mostly situated within the adrenal medulla. In some specific situations (see below), anatomical imaging for PHEO can be performed with ultrasound (U/S).
PHEO that secrete only epinephrine are uncommon, although they are frequently found in patients with MEN 2 (56). Patients with PHEO that secrete only epinephrine have high plasma or urinary epinephrine or metanephrine levels, and almost always have an adrenal tumor. In these patients, CT or MRI of the abdomen are a first choice examination for the diagnostic localization of PHEO. On the other hand, norepinephine and normetanephrine can be secreted by PHEO localized both within and outside the adrenal gland (48). If no adrenal masses are seen, attention should be focused initially to the paraspinous area (57). The majority of paragangliomas occur in the paraaortic region or around the renal hilum and may be visible on CT/MRI (57).
CT imaging
Adrenal PHEO of 0.5-1.0 cm or larger or metastatic PHEO at least 1.0 -2.0 cm in size can be detected by CT (36, 58), preferably with 2-to 5-mm-thick scanning sections (59). As most adrenal PHEO tumors have a diameter of at least 3 cm, they can be readily visualized with CT (Fig. 1A) . Adrenal adenomas can be differentiated from metastases with CT densitometry (60 -62). More particularly, a homogenous mass with a density measurement of less than 10 Hounsfield units (HU) on an unenhanced CT is most probably an adenoma (62), whereas if the mass is inhomogeneous and/or has a density measurement of 10 HU or more, the diagnosis is uncertain. Although nonfunctioning adenoma is the most common possibility, a metastasis or functioning tumor should also be considered. For cases with inconclusive clinical and biochemical results, further imaging assessment should be sought using washout after administration of contrast medium (61, 63). Small 1-to 2-cm PHEO tumors are usually homogeneous in appearance, with soft tissue density (ϳ40 -50 HU) and show uniform enhancement with contrast (64). Larger PHEO tumors may undergo hemorrhage and can be inhomogeneous, and areas of low density can be seen after tumor necrosis (57, 64 -66).
Extraadrenal PHEO are located close to the inferior vena cava and the abdominal aorta and alongside the sympathetic ganglia and Zuckerkandl's organ (7-10%) , between the inferior mesenteric artery and the aortic bifurcation, in the mediastinum (1%), or near the urinary bladder (1%) (33, 59). Thus, CT of the abdomen and pelvis should be performed first, followed by chest and neck imaging if this CT is negative (33, 66 -73). Spiral CT is preferred for small thoracic tumors.
The advantages of CT in the localization of PHEO are the moderate cost and its high sensitivity, which varies between 85-94% if a PHEO is located in the adrenal gland (19, 58, 74, 75) . Sensitivity for detecting extraadrenal, metastatic, or recurrent PHEO is about 90% before surgery (58, 76, 77). The sensitivity of CT may decrease to about 77% due to postoperative changes (35, 77). Additionally, the specificity of CT in excluding PHEO has been shown to be limited in some studies, from 29 -50% (75, 78, 79). Nevertheless for lesions limited to the adrenal glands, unenhanced CT followed by contrast-enhanced and delayed contrast-enhanced CT imaging yields a sensitivity of 98% and a specificity of 92% (63, 80). CT shows the structures surrounding a PHEO and permits exact localization of the tumor, although intraabdominal foreign bodies, such as surgical clips, may distort imaging findings (81, 82). In some patients with PHEO, CT may be negative or have equivocal findings, whereas MRI exams are positive (83, 84), but these cases are rare, especially in patients with no history of previous operation. Traditionally, ␣-and possibly also ␤-adrenergic receptor antagonist administration is advised for patients with biochemically proven PHEO to safely give ionic monomeric iv contrast for enhanced CT examination (64, 85, 86). However, no rise in plasma catecholamines was observed in 10 patients with PHEO who were given ioexol, a nonionic contrast medium, iv (85), so even contrast-enhanced CT does not pose a significant risk of a hypertensive crisis.
If a high quality, unenhanced and delayed enhanced, CTs are performed and the PHEO tumor is localized, there is no need to proceed to MRI, but functional imaging is required to confirm that a tumor is indeed PHEO and to rule out metastatic disease. If the CT is negative, in a patient with biochemically proven PHEO, MRI should be performed. MRI should be substituted for CT in children, pregnant women, and situations where radiation exposure must be minimized (87). Other situations where MRI is needed in addition to/ instead of CT are described below.
MRI imaging
Another imaging modality that is widely used in the diagnostic work-up of adrenal PHEO or detection of metastatic disease is MRI, with or without gadolinium enhancement (36, 58, 88). On MRI T1 sequences, PHEO have a signal like those of the liver, kidney, and muscle and can be differentiated with ease from adipose tissue. Chemical shift MRI characterizes adrenal masses based on the presence of fat in benign adenomas and the absence of fat in PHEO, metastases, hemorrhagic pseudocysts, or malignant tumors (89 -95). The hypervascularity of PHEO makes them appear characteristically bright, with a high signal on T2 sequence (Fig. 1B) and no signal loss on opposed phase images (Fig. 1B) (96) . More particularly, almost all PHEO have a more intense signal than that of the liver or muscle and often more intense than fat on T2-weighted images (57, 65, 97) . However, such intense signals can be elicited by hemorrhages or hematomas, adenomas, and carcinomas, so an overlap with PHEO must be considered (98 -101) , and specific additional imaging is needed to confirm that the tumor is PHEO. Atypical PHEO may show medium signal quality on T2-weighted images and an inhomogeneous appearance, especially if they are cystic (102) .
Among the advantages of MRI imaging of PHEO are its high sensitivity in detecting adrenal disease (93-100%) (19, 74, 103) and the lack of exposure to ionizing radiation. MRI is a good imaging modality for the detection of intracardiac, juxtacardiac, and juxtavascular PHEO, because it reduces cardiac and respiratory motion-induced artifacts (102) , whereas the use of T2 sequences enables better differentiation from surrounding tissues (104) . MRI can be carried out with or without using iv contrast agents (which are nevertheless very safe and do not cause the release of catecholamines) (105) (106) (107) , and thus no preparation with adrenergic blockade is necessary. MRI offers the possibility of multiplanar imaging and superior assessment of the relationship between a tumor and its surrounding vessels (the great vessels in particular) compared with CT, rendering this modality of utmost importance in the evaluation of patients with PHEO in these areas, especially to rule out vessel invasion (75). However, its overall sensitivity for detection of extraadrenal, metastatic, or recurrent PHEO is lower compared with that of adrenal disease (90%) (58, 75, 76, 108). Although some researchers have reported high specificity of MRI in excluding PHEO (100%) (79), in most reports the specificity of this modality has been shown to be limited to about 50% (74, 75). Additionally, MRI is a more expensive imaging modality than CT.
MRI should be used as the initial imaging procedure for imaging PHEO in children or during pregnancy (36, 108, 109), because it does not involve any radiation exposure, or in the case of known allergy to CT contrast agents.
U/S imaging
On U/S imaging, PHEO are usually seen as well defined, round or ovoid masses that demonstrate low echogenicity and homogenous consistency (64, 110). Large PHEO tumors frequently undergo hemorrhage or necrosis, and in this case homogeneity is lost (64). The sensitivity of U/S in evaluating PHEO has been assessed in relatively small numbers of patients and has been reported to be 83-89% (87, 111). To the best of our knowledge, extensive studies on the specificity of modern U/S techniques in the diagnosis of PHEO have not been performed, but it is believed to be low, as in older studies where the overall specificity for adrenal tumors was about 60% (112) . As U/S is a modality with no radiation exposure, it can be a first-line choice in the diagnostic work-up of PHEO in selected patients, such as pregnant women (113, 114) , infants, and children (34), but it is not superior to MRI. The low cost and ease of using U/S make this imaging modality a sound choice in the initial evaluation of patients suspected of having PHEO in the neck (115) . However, 10% of PHEO are cystic, and although they are readily seen with U/S, those located in the adrenal gland must be differentiated from upper pole renal cysts and hepatic cysts (34). Familial/hereditary causes of PHEO (such as MEN 2 syndrome, von Hippel-Lindau disease, or neurofibromatosis type 2) and possibly, in part, referral bias may account for the high prevalence of multifocal (adrenal and extraadrenal) or only extraadrenal PHEO reported in studies of children (diagnosed in up to 30 -43% of cases) (6, 8 -12) . As U/S provides limited views of the abdomen (108), it is inherently insensitive for imaging extraadrenal PHEO and cannot rule out multifocal disease. Similar to CT/MRI, the presence of surgical clips, distorted anatomy, or inadequate preparation of the patient may also render the interpretation of U/S images difficult.
In summary, this modality is not suitable for evaluating adult patients, and we do not recommend it unless under specific conditions (e.g. pregnancy) and in cases where CT and MRI are not available.
Functional imaging
Adrenal masses are present in about 5-9% of the general population (21, 22, 116, 117). Although most adrenal masses are benign, nonfunctional incidentalomas, about 6.5% of incidentally discovered adrenal masses are indeed PHEO (1-3). Thus, most adrenal abnormalities are not PHEO, highlighting the need for specific diagnostic imaging after anatomical studies are performed in patients with suspicion of PHEO. Additionally, as previously stated, there is no consensus on the existence of absolute clinical, imaging, or laboratory criteria to predict malignancy and multiplicity of PHEO (26 -28). Thus, in patients diagnosed with PHEO, the need to exclude metastatic disease or multiple tumors is important. This need might be fulfilled with functional imaging modalities using various radiopharmaceuticals that provide physicians with whole body, PHEO-specific, scans. Nuclear medicine imaging is also important in localizing PHEO in patients in whom anatomic imaging is negative and in the detection of metastatic lesions. However, all functional imaging methods are hampered by the excretion of radioisotopes in urine (118 -121) , thus lowering their ability to localize PHEO close to the kidneys, the head of the pancreas, or the urinary bladder.
PHEO cells usually abundantly express specific catecholamine plasma membrane and vesicular transporter systems, enabling imaging with [
131 I]-and [ 123 I]MIBG, as well as with several PET ligands (118, 120) . In Table 1 , we present a list of available radiopharmaceuticals for localization of PHEO. Some are already in clinical use, whereas newer ones are currently undergoing evaluation (122) (123) (124) .
MIBG imaging
MIBG is an aralkylguanidine that resembles norepinephrine. Radioactive labeling is performed with the iodine isotopes 131 I and 123 I at the meta-position of the benzoic ring. Like norepinephrine, MIBG is taken into sympathomedullary tissues mainly by a noradrenergic transporter system and into intracytoplasmic vesicles through a vesicular transporter system. MIBG is thus accumulated within adrenergic tissues. However, MIBG does not show any appreciable Normally, the myocardium, spleen, liver, urinary bladder, lungs, and salivary glands, being rich in sympathetic innervation, show MIBG uptake after 24 h (137-142). On some occasions, the large intestine (143) and the cerebellum (144, 145) may also show MIBG accumulation. Moreover, the normal adrenal medulla may show [ 123 I]MIBG uptake (in as many as 32-75% of patients after 24 h) (130, 140) . The pattern of [ 123 I]MIBG uptake may be asymmetrical between the left and right adrenals, and caution should be applied in interpreting the images obtained, particularly to avoid unnecessary or misguided surgery. More rarely, [ 131 I]MIBG uptake is seen in normal adrenal medulla (16% of scans after 48 h) (141) . Some of the MIBG is taken up by platelets, and thrombocytopenia may occur (146, 147) . Most of the injected MIBG is excreted via the kidneys, with minimal excretion in sweat, saliva, and feces (118, 148 
PET imaging
PET imaging is performed within minutes or hours after the injection of short-lived positron-emitting agents. Low radiation exposure and superior spatial resolution are among the advantages of PET, whereas the cost and limited availability of the radiopharmaceuticals and PET equipment (including the radionuclide-producing cyclotron) still prohibit more widespread use. 
Somatostatin receptor scintigraphy
Somatostatin receptors have seven transmembrane domains and are G protein coupled (177) . Five types of somatostatin receptors are recognized. Types 1, 2, and 5 are abundantly expressed in different neuroendocrine tumors, whereas type 4 shows variable expression, and type 3 shows low expression in these tumors (177, 178) . Up to 73% of PHEO cells express somatostatin receptors (predominantly types 2 and 4) (47), like other neuroendocrine tumors, as shown by studies using different techniques, such as radioligand binding, immunohistochemistry, in situ hybridization, Northern blotting, ribonuclease protection, and quantitative RT-PCR (179 -181) . Octreotide is an eight-amino acidlong peptidic analog of somatostatin that is metabolically stable and has highest affinity for type 2 somatostatin receptors, high affinity for type 5 receptors, moderate affinity for type 3 receptors, and no affinity for types 1 and 4 receptors of somatostatin (182) . [ 111 In]diaminetriaminepentacetate (DTPA), with a half-life of 2.8 d and ␥-ray emissions of 173 and 247 keV, is usually used for labeling octreotide. Octreotide is internalized through a receptor-mediated process, and conjugation with DTPA (which is a polar molecule) prevents its passage across the lysosomal and other cell membranes (177) .
Octreotide is given iv in doses of 3-6 mCi (111-222 MBq), and scintigraphic views are obtained at 4, 24, and 48 h, as needed. SPECT imaging should be performed. Octreotide is predominantly (85%) cleared by the kidneys within 24 h (119, 121) . Sites of physiological uptake include mammary glands, liver, spleen, kidneys, bowel gall bladder, pituitary, thyroid, and salivary glands (119 -121, 183) . Infections, inflammation, and recent surgery cause false positive results (184, 185) . Inflamed joints in patients with arthritis also show increased octreotide uptake (34).
Somatostatin receptor scintigraphy (with either [ 123 I]Tyr3-octreotide or [ 111 In]DTPA-octreotide) has been used in patients with PHEO (46, 186 -191) . However, the interpretation of the Octreoscan is hampered by the normal presence of somatostatin receptors in a wide range of tissues as well as in inflammatory sites. Another drawback to imaging of intraadrenal PHEO with Octreoscan is the significant degree of octreotide uptake seen in the kidneys (192, 193) , which reduces the scintigraphic sensitivity of [ 111 In]DTPA-octreotide for small tumors in the perirenal region (192, 193) , and although the infusion of amino acid solutions such as lysine and arginine can lower renal uptake, this technique is not yet widely implemented (194 (156, 165, 188, 190, 191 (42, 43) (Pacak, K., unpublished observations). In such cases, Octreoscan should be performed to localize PHEO, because this modality has detected lesions in patients with MIBGnegative neuroendocrine tumors (156, 188, 191, 195) (Fig. 5) . This is more important, as more metastases of undifferentiated neuroendocrine tumors were positive on Octreoscan compared with metastases of histologically well differentiated neuroendocrine tumors (195) .
We currently do not recommend performing PET, MIBG scintigraphy, or Octreoscan as the first imaging modalities in the diagnostic localization of PHEO, because of limited availability compared with CT/MRI and the long waiting time (up to 72 h) for obtaining imaging views, although these modalities are of utility in further diagnostic work-up of PHEO (156, 187) .
Proposed imaging algorithm
A generally accepted and cost-effective approach for the diagnostic localization of PHEO has yet to be established. Biochemical confirmation of the disease is crucial (36, 48, 49) and is best achieved by measuring plasma metanephrine and normetanephrine, ensuring, however, adequate withdrawal from medications that interfere with these measurements and lead to false positive results, such as phenoxybenzamine, tricyclic antidepressants, and ␤-adrenoreceptor blockers (196) . Additional biochemical confirmation can be obtained using the clonidine test coupled with measurement of plasma metanephrine and normetanephrine (196, 197) . Evaluation aiming to localize PHEOs in the absence of biochemical corroboration is justified only when there is suspicion of familial disease, particularly at a stage before these tumors secrete significant amounts of catecholamines (197) .
In Fig. 6 , we propose the use of anatomical imaging methods (either CT or MRI) for initial imaging of the adrenals in patients with biochemically proven PHEO. In some cases, such as in children or during pregnancy, MRI is preferred, but ultrasound may also be considered.
As far as CT is concerned, lesions on unenhanced CT with attenuation values lower than 10 HU exclude the presence of PHEO, whereas those with values higher than 10 HU may be followed by contrast-enhanced and delayed enhanced CT examinations (61, 63). If MRI is chosen as the initial anatomical imaging modality, T1 (with chemical shift) and T2 sequences should be performed. Negative CT or MRI imaging of the adrenals, abdomen, and pelvis should be followed by additional CT scans, except where this modality in contraindicated, such as in children and during pregnancy, where MRI is preferred. If all CT scans are negative, little is to be gained by performing MRI, except in patients with previous surgery that may result in distorted anatomy.
The presence of PHEO should always be ruled out or confirmed with functional imaging (even if CT and MRI are negative, but PHEO is biochemically proven If these are also negative, the patient probably has an unusual type of PHEO (in which tumor cells do not express the norepinephrine transporter system or may have a low number of catecholamine storage granules) or malignant PHEO, and scintigraphy with nonspecific ligands, such as somatostatin receptor scintigraphy with Octreoscan or FDG PET, should be carried out. Venous sampling coupled with measurement of catecholamines or, preferably, metanephrines (35, 36, 50) to localize the tumor through the discovery of a secretory gradient is an ultimate modality to be used with caution in selected cases where all imaging methods have failed. This is technically demanding and is best conducted at specialized centers (6, 198 -214) . If access to such centers is not feasible, then a repeat noninvasive localization work-up after 2-6 months is a more attractive and preferable choice. 
